Is gender-neutral vaccination superior for eradication of oncogenic strains of HPV?

  • Vänskä S & al.
  • J Infect Dis
  • 11 Mar 2020

  • curated by Priscilla Lynch
  • Univadis
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Gender-neutral vaccination is superior for eradication of oncogenic strains of human papillomavirus (HPV), suggest the results of a community-randomised modelled trial published in the Journal of Infectious Diseases.

Researchers randomised 33 Finnish communities into gender-neutral HPV16/18 vaccination, girls-only HPV16/18 vaccination, and hepatitis B-virus vaccination arms.

In 2007-2010, 11,662/20,513 of 40,852/39,420 resident boys/girls from 1992-1995 birth cohorts consented. In 2010-14, cervicovaginal samples from vaccinated and unvaccinated girls at age 18.5 years were typed for HPV6/11/16/18/31/33/35/39/45/51/52/56/58/59/66/68. Vaccine efficacy (VE) for vaccinated girls, herd effect (HE) for unvaccinated girls, and the protective effectiveness (PE) for all girls, were estimated. The researchers extended the community-randomised trial results about vaccination strategy with mathematical modelling to assess HPV eradication.

The HE and PE estimates in the 1995 birth cohort for HPV18/31/33 were significant in the gender-neutral arm, and 150% and 40% stronger than in the girls-only arm. Concordantly, HPV18/31/33 eradication was predicted in adolescents/young adults in already 20 years with 75% coverage of gender-neutral vaccination. With the 75% coverage, eventual HPV16 eradication was also predicted, but only with the gender-neutral strategy.

“The results have definitely influenced the decision about offering HPV vaccination to boys [in Sweden in 2020], which more and more countries are also deciding,” said Matti Lehtinen, who led the study.